How Can We Improve the Existing Vaccine for Tuberculosis to Combat the Growing 
Number of Multi-Resistant Strains?

Kaufmann, Stefan H. E.

doi:10.21036/LTPUB10207

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Bitte beachten Sie, dass eine neuere Version dieses Datensatzes verfügbar ist:
https://pure.mpg.de/pubman/item/item_2300815_5

DetailsÜbersicht

Freigegeben

Film

How Can We Improve the Existing Vaccine for Tuberculosis to Combat the Growing Number of Multi-Resistant Strains?

MPG-Autoren

/persons/resource/persons81969

Kaufmann, Stefan H. E.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

Externe Ressourcen

https://lt.org/publication/how-can-we-improve-existing-vaccine-tuberculosis-combat-growing-number-multi-resistant
(Multimedia)

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Kaufmann, S. H. E. (2016). How Can We Improve the Existing Vaccine for Tuberculosis to Combat the Growing Number of Multi-Resistant Strains? doi:10.21036/LTPUB10207.

Zitierlink: https://hdl.handle.net/11858/00-001M-0000-002B-BB95-9

Zusammenfassung

Each year 1.5 million people die of tuberculosis thus making it the number one killer of all contagious diseases. With the number of multi-resistant tuberculosis growing, currently available treatments are no longer as effective as they used to be. The existing vaccine does not protect against pulmonary tuberculosis which is the most common form of the disease and easily transmittable. In this video, STEFAN H. E. KAUFMANN describes how this existing vaccine was modified to trigger an additional component of the cellular immune response. The researchers showed that it achieved profound reduction of bacterial load in the lung and an excellent safety profile in preclinical studies. The vaccine candidate is currently undergoing clinical trials to be approved for humans.